交通医学
交通醫學
교통의학
MEDICAL JOURNAL OF COMMUNICATIONS
2015年
2期
128-130,134
,共4页
不稳定型心绞痛%动脉粥样硬化%Omega-3多不饱和脂肪酸%酶联免疫吸附试验
不穩定型心絞痛%動脈粥樣硬化%Omega-3多不飽和脂肪痠%酶聯免疫吸附試驗
불은정형심교통%동맥죽양경화%Omega-3다불포화지방산%매련면역흡부시험
Unstable Angina%atherosclerosis%Omega-3 PUFAs%enzyme-linked immunosorbent assay
目的：观察Omega-3多不饱和脂肪酸对不稳定型心绞痛患者血清炎症因子的影响及疗效。方法：选择未行冠脉成形术（percutaneous coronary intervention，PCI）治疗的不稳定型心绞痛（unstable angina，UA）患者54例，随机分为Omega-3多不饱和脂肪酸组及安慰剂治疗组各27例。分别于入院时及治疗8周后检测患者空腹血清中白介素6、肿瘤坏死因子α、高敏C反应蛋白、IL-10及转化生长因子β等炎症因子表达变化；记录不良反应及半年内心血管事件发生率。结果：治疗后Omega-3组血清IL-6、TNF-α及CRP表达水平均较治疗前显著下降（P<0.05），IL-10、TGF-β表达显著上升（P<0.05）。对照组各炎症因子水平治疗前后变化差异无统计学意义（P>0.05)；与对照组比较， Omega-3组用药8周后血清IL-6、TNF-α及CRP表达水平显著降低，IL-10、TGF-β表达显著上升；差异均有统计学意义（P<0.05）。治疗后半年内Omega-3组心血管终点事件发生率较对照组降低，但差异无统计学意义（P>0.05），两组不良反应发生比较差异无统计学意义。结论：不稳定型心绞痛患者口服Omega-3多不饱和脂肪酸能显著抑制炎症，纠正促炎和抑炎失衡，发挥其抗动脉粥样硬化作用。
目的：觀察Omega-3多不飽和脂肪痠對不穩定型心絞痛患者血清炎癥因子的影響及療效。方法：選擇未行冠脈成形術（percutaneous coronary intervention，PCI）治療的不穩定型心絞痛（unstable angina，UA）患者54例，隨機分為Omega-3多不飽和脂肪痠組及安慰劑治療組各27例。分彆于入院時及治療8週後檢測患者空腹血清中白介素6、腫瘤壞死因子α、高敏C反應蛋白、IL-10及轉化生長因子β等炎癥因子錶達變化；記錄不良反應及半年內心血管事件髮生率。結果：治療後Omega-3組血清IL-6、TNF-α及CRP錶達水平均較治療前顯著下降（P<0.05），IL-10、TGF-β錶達顯著上升（P<0.05）。對照組各炎癥因子水平治療前後變化差異無統計學意義（P>0.05)；與對照組比較， Omega-3組用藥8週後血清IL-6、TNF-α及CRP錶達水平顯著降低，IL-10、TGF-β錶達顯著上升；差異均有統計學意義（P<0.05）。治療後半年內Omega-3組心血管終點事件髮生率較對照組降低，但差異無統計學意義（P>0.05），兩組不良反應髮生比較差異無統計學意義。結論：不穩定型心絞痛患者口服Omega-3多不飽和脂肪痠能顯著抑製炎癥，糾正促炎和抑炎失衡，髮揮其抗動脈粥樣硬化作用。
목적：관찰Omega-3다불포화지방산대불은정형심교통환자혈청염증인자적영향급료효。방법：선택미행관맥성형술（percutaneous coronary intervention，PCI）치료적불은정형심교통（unstable angina，UA）환자54례，수궤분위Omega-3다불포화지방산조급안위제치료조각27례。분별우입원시급치료8주후검측환자공복혈청중백개소6、종류배사인자α、고민C반응단백、IL-10급전화생장인자β등염증인자표체변화；기록불량반응급반년내심혈관사건발생솔。결과：치료후Omega-3조혈청IL-6、TNF-α급CRP표체수평균교치료전현저하강（P<0.05），IL-10、TGF-β표체현저상승（P<0.05）。대조조각염증인자수평치료전후변화차이무통계학의의（P>0.05)；여대조조비교， Omega-3조용약8주후혈청IL-6、TNF-α급CRP표체수평현저강저，IL-10、TGF-β표체현저상승；차이균유통계학의의（P<0.05）。치료후반년내Omega-3조심혈관종점사건발생솔교대조조강저，단차이무통계학의의（P>0.05），량조불량반응발생비교차이무통계학의의。결론：불은정형심교통환자구복Omega-3다불포화지방산능현저억제염증，규정촉염화억염실형，발휘기항동맥죽양경화작용。
Objective:To evaluate the changes and effects of Omega-3 polyunsaturated fatty acids(PUFAs) on serum levels of inflammatory factors in patients with unstable angina(UAP). Methods:54 patients with UAP admitted between Mar 2013 and June 2014 were randomly divided into the Omega-3 PUFAs group(n=27) who received Omega-3 PUFAs, and the placebo group(n=27). The serum levels of inflammatory factors such as tumor necrosis factor(TNF-α), interleukin 6(IL-6), High sensitivity C reactive protein(Hs-CRP), IL-10 and transforming growth factorβ(TGF-β)were measured before and after treatment, and Major adverse cardiovascular event and side effects were observed. Results:after treatment, The serum expression levels of TNF-α, IL-6 and CRP in the Omega-3 PUFAs group were lower than the placebo group(P<0.05), and the serum expression levels of IL-10 and TGF-βwere higher than in the placebo group(P<0.05). The incidence rate of major adverse cardiovascular event in the Omega-3 PUFAs group was lower than in the conventional interventional group in half a year (P<0.05) and side effects were similar between two groups. Conclusion:Taking Omega-3 PUFAs can depress the experssion of serum inflammatory factors in patients with UA, and treatment with Omega-3 PUFAs was safe and effective.
